MOLOGNI LUCA

Role
Associate professor  
Academic disciplines
Cellular and Experimental Biology (BIOS-10/A)
Scientific-Disciplinary Group:
CELLULAR AND EXPERIMENTAL BIOLOGY (05/BIOS-10)
Office phone
Room:
  • U08, Floor: 4, Room: LABORATORIO 4.10
  • U08, Floor: 4, Room: 4043

Publications

  • Crippa, V., Fontana, D., Civettini, I., Mologni, L., Piazza, R., Gambacorti Passerini, C., et al. (2024). Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer. Intervento presentato a: AACR Annual Meeting 2024 - April 5 - 10, 2024, San Diego, Ca, Usa. Detail

  • Fontana, D., Malighetti, F., Villa, M., Zambon, A., Gambacorti-Passerini, C., Mologni, L. (2024). Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. LEUKEMIA, 38(8), 1843-1847 [10.1038/S41375-024-02282-Y]. Detail

  • Villa, M., Malighetti, F., Sala, E., Sharma, G., Arosio, G., Gemelli, M., et al. (2024). New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ PRECISION ONCOLOGY, 8(1) [10.1038/s41698-024-00498-w]. Detail

  • Villa, M., Geeta, G., Malighetti, F., Mauri, M., Arosio, G., Cordani, N., et al. (2024). Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma. BRITISH JOURNAL OF CANCER [10.1038/s41416-024-02881-7]. Detail

  • Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD, 143(14), 1399-1413 [10.1182/blood.2023021349]. Detail

Research projects

Investigation of the co-mutational landscape of naïve and drug-resistant ALK+ tumors: prognostic and therapeutic value - IV annualità
Year: 2023
Grantors: FONDAZIONE AIRC
Targeting AML by Liposome encapsulated Kinase inhibitors (TALK)
Year: 2023
Call: FAQC 2023 - seconda finestra
Grantors: Università degli Studi di MILANO-BICOCCA
Investigation of the co-mutational landscape of naïve and drug-resistant ALK+ tumors: prognostic and therapeutic value - III annualità
Year: 2022
Grantors: FONDAZIONE AIRC
PNRR per la Missione 4, componente 2 Investimento 1.1- Avviso 104/2022 | Overcoming treatment resistance mechanisms in ALK-driven cancers
Year: 2022
Call: Bando PRIN 2022
Grantors: MINISTERO DELL'UNIVERSITA' E DELLA RICERCA (MUR)
Investigation of the co-mutational landscape of naïve and drug-resistant ALK+ tumors: prognostic and therapeutic value - II annualità
Year: 2021
Call: CALL FOR PROPOSALS 2020. INVESTIGATOR GRANT (IG)
Grantors: FONDAZIONE AIRC